Natco Pharma Share Price Jumps 11% After CDSCO Approval for Semaglutide Injection in India

Natco Pharma share price (NSE: NATCOPHARM) rose about 11% in early trading on the BSE, reaching an intraday high near ₹914. The stock outperformed the broader market, which remained almost flat during the session.

The rally followed the company’s announcement that it received approval from the Central Drugs Standard Control Organisation to manufacture and sell generic Semaglutide injections in India.

Product Launch Plans

Natco Pharma said it plans to introduce the Semaglutide injection in the Indian market by March 2026.
This medicine is used to treat adults with type 2 diabetes whose blood sugar levels are not properly controlled through diet and exercise alone.

USFDA Inspection Update

On February 13, 2026, the company also received an Establishment Inspection Report from the US Food and Drug Administration for its API manufacturing unit in Manali, Chennai.
The inspection had earlier listed seven observations under Form 483. It is now classified as Voluntary Action Indicated (VAI), meaning the facility can continue operating while the company completes corrective actions.

Natco Pharma Q3FY26 Financial Performance

During the December quarter, Natco Pharma reported:

• Net profit of ₹151.3 crore, up from ₹132.4 crore year-on-year
• Revenue of ₹705.4 crore, compared with ₹651.1 crore in the same period last year

These results show moderate growth in both earnings and revenue.

Read More: RBI to Overhaul Lead Bank Scheme for Enhanced Effectiveness!

About Natco Pharma

Headquartered in Hyderabad, Natco Pharma develops and manufactures generic and branded medicines, speciality pharmaceuticals, active pharmaceutical ingredients, and crop protection products.

The company focuses strongly on research-driven oncology therapies and limited-competition molecules in the US market. It operates nine manufacturing plants and two R&D centres in India, supplying products to around 50 global markets with approvals from major international regulators.

Conclusion

The CDSCO approval for generic Semaglutide is a positive development for Natco Pharma and strengthening its diabetes treatment portfolio. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.